Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Beats Expectations By $0.21 EPS

Viridian Therapeutics (NASDAQ:VRDN) issued its quarterly earnings data on Wednesday. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21, FiscalAI reports. The business had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%.

Here are the key takeaways from Viridian Therapeutics’ conference call:

• LUMVOA generated $24.7 million in net product revenue in its first launch quarter, with more than 100 patients having started treatment by September 30. Management said the revenue was demand-driven, not primarily inventory stocking.
• The company reported payer policies covering 30% of covered lives by quarter-end, with parity access in almost all cases, and said it remains on track for broad coverage six to nine months after launch. CMS assigned LUMVOA a permanent J-code effective January 1, 2027.
• Management called the launch encouraging but emphasized it is still early and said uptake will need to be assessed over subsequent quarters; it declined to provide Q4 guidance or quantify market share.
• Viridian said it remains on track to submit elegrobart’s BLA in Q1 2027, expects to begin a Phase I trial of VRDN-292 in Graves’ disease later this quarter, and plans to share first-in-human data for VRDN-008 later this quarter.
• The company ended the quarter with just over $955 million in cash, cash equivalents, and marketable securities, which management said is sufficient to fund current business plans through profitability.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock opened at $28.55 on Friday. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $21.88 and its two-hundred day moving average price is $21.83. Viridian Therapeutics has a 52 week low of $13.18 and a 52 week high of $34.29. The stock has a market cap of $3.23 billion, a PE ratio of -7.43 and a beta of 1.07.

Insiders Place Their Bets

In other news, insider Jennifer Tousignant sold 14,212 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on VRDN. HC Wainwright boosted their price target on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada increased their price objective on shares of Viridian Therapeutics from $38.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday. Wells Fargo & Company increased their price objective on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Thursday. Truist Financial raised their price objective on shares of Viridian Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Leerink Partners boosted their target price on Viridian Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a report on Thursday. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Viridian Therapeutics News Summary

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, better than analysts’ expected loss of about $1.01, and revenue of $25.75 million, above estimates. The loss was wider than the $0.34 per-share loss a year earlier, but the earnings beat helped support investor sentiment. Zacks Q3 earnings report
• Positive Sentiment: Analysts raised price targets, reinforcing bullish expectations: Leerink Partners lifted its target to $54, while RBC and Truist raised theirs to $41 and $42, respectively. Wedbush also raised its target to $42, and HC Wainwright increased its target from $22 to $40, maintaining a Buy rating. Leerink Partners recommendations Wedbush price target report HC Wainwright recommendations
• Positive Sentiment: Viridian is targeting broader coverage for its Lumvoa launch within 6–9 months and expects to submit an elegrobart biologics license application in Q1 2027. Progress on launch execution and the filing could provide future catalysts. Lumvoa and elegrobart timeline
• Negative Sentiment: The company remains loss-making, and one recent analysis argued that VRDN may be overvalued even with its new launch—raising the risk that launch expectations are already reflected in the shares. Yahoo Finance valuation analysis

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.